Clinical trials: Treatment Resistant
HIV Infections
Study Assessing Dolutegravir in HIV-1 Infected Subjects With Virus Resistant to Raltegravir and/or Elivitegravir
Study ING116529 is a multicenter, randomized, study with an initial 7 day placebo- controlled, functional monotherapy phase to quantify the antiviral activity attributable to dolutegravir (DTG) in HIV-1 infected, ART-experienced…
- Trial name
- VIKING-4 (NCT01568892)
- Testing
- Dolutegravir 50 mg twice daily
- Where
- 25 sites in United States
- Volunteers
- 30 people
- Sponsor
- ViiV Healthcare
Prostate Cancer
GTx-758 on Serum Prostate-specific Antigen (PSA) in Men With Castrate Resistant Prostate Cancer
The purpose of this study is to assess the effect of GTx-758 on Serum Prostate-specific antigen (PSA) levels in men with castrate resistant prostate cancer who are maintained on androgen deprivation therapy (Serum PSA response…
- Trial name
- NCT01420861
- Testing
- GTx-758
- Where
- 7 sites in United States
- Volunteers
- 18 people
- Sponsor
- GTx
HIV Infections
A Long Term Safety Study of Apricitabine in HIV-infected Patients
This study will examine the long term safety of apricitabine in HIV-1 infected patients from studies AVX-301 or AVX-302. Eligible patients are those who have either (a)completed studies AVX-301 or AVX-302; or (b)met the criteria…
- Trial name
- NCT00686270
- Testing
- apricitabine
- Sponsor
- Avexa
Premenopause, Iron-deficiency
A Clinical Study on Adherence and Efficacy of Different Doses of Active Iron in Treatment Resistant Subjects
A randomized, placebo controlled, parallel group, double blind study to compare the 3-month adherence and efficacy of Active Iron in subjects with or at-risk of iron deficiency and a history of intolerance to oral iron.
- Conditions
- Premenopause, Iron-deficiency, Iron Adverse Reaction, Iron Deficiency Anemia
- Trial name
- NCT04778072
- Testing
- Ferrous sulfate 14mg once daily, Ferrous sulfate 25mg once daily, Ferrous sulfate 25mg twice daily
- Where
- Ireland
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Solvotrin Innovations Ltd
Chronic Hepatitis B
A Efficacy and Safety Study of Adefovir Dipivoxil to Treat Chinese Patients With HBeAg+ve Chronic Hepatitis B
The purpose of this study is to determine whether Adefovir Dipivoxil is effective and safe in treatment of Chinese Patients with HBeAg positive Chronic Hepatitis B for 5 years.
- Trial name
- NCT00857675
- Testing
- AAAA, AAPA, PAAA
- Where
- 10 sites in China
- Volunteers
- 480 people
- Sponsor
- GlaxoSmithKline
Chronic Myeloid Leukemia, Acute Lymphocytic Leukemia
Safety and Tolerability Study of INNO-406 to Treat Chronic Myeloid Leukemia or Acute Lymphocytic Leukemia
The purpose of this study is to determine the safety and effectiveness of INNO-406 in adult patients with imatinib-resistant or intolerant Philadelphia chromosome-positive (Ph+) leukemias.
- Trial name
- NCT00352677
- Testing
- INNO-406
- Where
- 6 sites in United States, Germany and 1 more
- Volunteers
- 100 people
- Sponsor
- CytRx
Metastatic Castration-Resistant Prostate Cancer
XmAb®20717 (Vudalimab) Alone or in Combination With Chemotherapy or Targeted Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer
This Phase 2 study will investigate the safety and clinical activity of vudalimab (XmAb20717) alone or in combination with standard of care anticancer therapies in patients with metastatic castration-resistant prostate cancer…
- Trial name
- NCT05005728
- Testing
- vudalimab + carboplatin + cabazitaxel, vudalimab + olaparib, vudalimab monotherapy
- Where
- 26 sites in United States
- Volunteers
- 72 people
- Sponsor
- Xencor, Inc.
Castration-resistant Prostate Cancer
Disitamab Vedotin in the Treatment With HER2- Expression, Subjects With Locally Advanced or Metastatic Castration-resistant Prostate Cancer
The purpose of this study is to evaluate the effectiveness of Disitamab Vedotin in the treatment of subjects with locally advanced or metastatic castration-resistant prostate cancer.
- Trial name
- NCT06227156
- Testing
- Disitamab Vedotin Injection
- Where
- 3 sites in China
- Volunteers
- 40 people
- Sponsor
- RemeGen Co., Ltd.
Treatment Resistant Depressive Disorder
A Study to Evaluate the Safety and Efficacy of Intranasal Esketamine in Treatment-resistant Depression
The purpose of this study is to assess the efficacy and dose response of intranasal esketamine (Panel A: 28 mg, 56 mg, and 84 mg and Panel B: 14 mg and 56 mg) compared with placebo in improving depressive symptoms in participants…
- Trial name
- SYNAPSE (NCT01998958)
- Testing
- Esketamine 14 mg, Esketamine 28 mg, Esketamine 56 mg
- Where
- 25 sites in United States, Belgium and 1 more
- Volunteers
- 108 people
- Sponsor
- Janssen Research & Development, LLC
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer
To evaluate whether Fuzuloparib plus AA-P is superior to placebo plus AA-P as first-line treatment by assessment of radiographic progression-free survival (rPFS) in mCRPC subjects unselected for deoxyribonucleic acid (DNA) damage…
- Trial name
- NCT04691804
- Testing
- Fuzuloparib , Abiraterone acetate and Prednisone
- Where
- 147 sites in United States, Australia and 11 more
- Volunteers
- 496 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Prostatic Neoplasms, Castration-Resistant
A Local Retrospective Observational Study to Evaluate the Treatment Patterns of mCRPC Patients in Belgium Treated With Radium-223
The aim of this non interventional study is to describe the proportion of Belgian mCRPC patients which were treated with 1 to 4 and 5 to 6 Radium-223 injections and the patient characteristics which are potentially associated…
- Trial name
- BELFIGO (NCT03563014)
- Testing
- Radium-223 (Xofigo, Bay88-8223)
- Where
- Belgium
- Volunteers
- 164 people
- Sponsor
- Bayer
Head and Neck Squamous Cell Carcinoma, Head and Neck Cancer
Oral AHR Antagonist in Combination With Nivolumab in Patients With PD-1 Resistant Metastatic or Recurrent Head and Neck Cancer
This is a phase 1b study in adult patients diagnosed with resistant or recurrent head and neck squamous cell carcinoma (HNSCC) designed to assess the safety and tolerability of IK-175 in combination with nivolumab.
- Conditions
- Head and Neck Squamous Cell Carcinoma, Head and Neck Cancer, Head Cancer, Neck Cancer
- Trial name
- NCT05472506
- Testing
- IK-175 + nivolumab
- Where
- 4 sites in United States
- Sponsor
- Ikena Oncology
Metastatic Castration-Resistant Prostate Cancer, Ovarian Cancer
CATCH-R: A Rollover Study to Provide Continued Access to Rucaparib
This protocol is designed to provide participants currently benefiting from rucaparib treatment in a Clovis-sponsored clinical study with continued access to treatment for as long as they continue to benefit.
- Conditions
- Metastatic Castration-Resistant Prostate Cancer, Ovarian Cancer, Epithelial Ovarian Cancer, Fallopian Tube Cancer
- Trial name
- CATCH-R (NCT04676334)
- Testing
- Rucaparib
- Where
- 25 sites in Canada, Israel and 4 more
- Volunteers
- 34 people
- Sponsor
- pharmaand GmbH
Bipolar Depression
Efficacy, Safety and Pharmacokinetic Study of Inhaled Esketamine in Treatment-resistant Bipolar Depression
The purpose of the study is to determine the efficacy, safety and pharmacokinetics of inhaled Esketamine in participants with treatment-resistant bipolar depression (TRBD).
- Trial name
- NCT03965871
- Testing
- Esketamine DPI - low dose, Esketamine DPI - medium dose, Esketamine DPI - high dose
- Where
- 12 sites in Poland
- Volunteers
- 88 people
- Sponsor
- Celon Pharma SA
Depression
AZD6765 for Treatment Resistant Depression
The purpose of this study is to determine whether treatment with AZD6765 will have an antidepressant effect with patients who have treatment resistant depression.
- Trial name
- NCT00491686
- Testing
- AZD6765
- Where
- 5 sites in United States
- Volunteers
- 34 people
- Sponsor
- AstraZeneca
Metastatic Castration Resistant Prostate Cancer (mCRPC)
AB-3028, a Programmable Circuit T Cell Therapy in Patients With Castration Resistant Prostate Cancer (CRPC)
This is a multi-center, open-label Phase 1/2 trial evaluating the safety and efficacy of AB-3028 in subjects with metastatic castration resistant prostate cancer (mCRPC).
- Trial name
- NCT07285694
- Testing
- AB-3028
- Where
- 9 sites in United States
- Volunteers
- 190 people
- Sponsor
- Arsenal Biosciences, Inc.
Treatment Resistant Depression
Safety, Tolerability, PK and Efficacy of Single Doses of NV-5138 in Healthy Volunteers and Subjects With Treatment-Resistant Depression
Randomized, two-part, placebo-controlled study of single ascending doses of NV-5138 in healthy volunteers, and a single dose of NV-5138 in subjects with Treatment-Resistant Depression (TRD)
- Trial name
- NCT03606395
- Testing
- NV-5138
- Where
- 9 sites in United States
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Navitor Pharmaceuticals, Inc.
Gynecologic Neoplasms, Epithelial Ovarian Cancer
PLX2853 as a Single Agent in Advanced Gynecological Malignancies and in Combination With Carboplatin in Platinum-Resistant Epithelial Ovarian Cancer
The purpose of this research study is to evaluate safety, pharmacokinetics, pharmacodynamics and preliminary efficacy of the investigational drug PLX2853 in Advanced Gynecological Malignancies with a Known ARID1A Mutation and…
- Trial name
- NCT04493619
- Testing
- PLX2853, Carboplatin
- Where
- 9 sites in United States, Canada
- Volunteers
- 37 people
- Sponsor
- Opna Bio LLC
Pressure Ulcer
Phage Therapy for the Prevention and Treatment of Pressure Ulcers.
This study will evaluate a topical bacteriophage therapy product (BACTELIDE) as an adjunct to standard therapy for the prevention and treatment of pressure ulcers colonized with S. aureus, P. aeruginosa, or K. pneumoniae species.
- Trial name
- NCT04815798
- Testing
- Bacteriophage-loaded Microcapsule Spray, Standard of Care
- Volunteers
- 69 people
- Sponsor
- Precisio Biotix Therapeutics, Inc.
COPD
A Study to Assess the Effects of PT003 and Placebo MDI on Specific Image Based Airway Volumes and Resistance in Subjects With Moderate to Severe COPD
Study to Evaluate the Effects of PT003 and Placebo MDI on Specific Image Based Airway Volumes and Resistance With Moderate to Severe COPD.
- Trial name
- NCT02643082
- Testing
- GFF MDI (PT003) 14.4/9.6μg
- Where
- Belgium
- Volunteers
- 20 people
- Sponsor
- Pearl Therapeutics, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.